Kolkhir, Pavel http://orcid.org/0000-0001-5380-8132
Elieh-Ali-Komi, Daniel
Metz, Martin http://orcid.org/0000-0002-4070-9976
Siebenhaar, Frank http://orcid.org/0000-0003-4532-1644
Maurer, Marcus http://orcid.org/0000-0002-4121-481X
Article History
Accepted: 19 August 2021
First Online: 5 October 2021
Competing interests
: P.K. was recently a speaker for Novartis and Roche. M.Me. was recently a speaker and/or adviser for Amgen, Aralez, ArgenX, Bayer, Beiersdorf, Celgene, Galderma, Menlo, Moxie, Novartis, Roche, Sanofi, Shire, Siennabio and Uriach. F.S. was recently a speaker and/or adviser for and/or has received research funding from Allakos, Blueprint, Celldex, Genentech, Novartis, Moxie and Uriach. M.Ma. was recently a speaker and/or adviser for and/or has received research funding from Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third HarmonicBio, UCB and Uriach. D.E.-A.-K. declares no competing interests.